Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

ANB032 was well tolerated across all doses with no safety signals observed; AD trial and all further investment in ANB032 will be discontinued; Anticipate top-line Phase 2b data i ...

Christopher Wray Will Step Down as F.B.I. Director President-elect Trump had already signaled his intention to replace Mr. Wray with a longtime loyalist, Kash Patel. U.S. Colleges Warn Foreign ...

US Bankers Are Cautious Towards Cryptos Despite Upcoming Pro-Crypto Administration ...